Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation
Osteoporosis and fractures are frequently encountered in patients with Crohn's disease. Study aimed to demonstrate a beneficial effect on bone density of the bisphosphonate risedronate
